Kazia Therapeutics Ltd ADR (KZIA)vsRegeneron Pharmaceuticals Inc (REGN)
KZIA
Kazia Therapeutics Ltd ADR
$8.08
+0.75%
HEALTHCARE · Cap: $89.24M
REGN
Regeneron Pharmaceuticals Inc
$973.36
+1.26%
HEALTHCARE · Cap: $95.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 889829% more annual revenue ($16.90B vs $1.90M). REGN leads profitability with a 28.5% profit margin vs 0.0%. KZIA appears more attractively valued with a PEG of 1.01. REGN earns a higher WallStSmart Score of 78/100 (B+).
KZIA
Hold36
out of 100
Grade: F
REGN
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for KZIA.
Margin of Safety
+38.3%
Fair Value
$1504.34
Current Price
$973.36
$530.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 312.4% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Strong operational efficiency at 40.5%
Revenue surging 36.3% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 29 of every $100 in revenue as profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : KZIA
The strongest argument for KZIA centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 312.4% demonstrates continued momentum. PEG of 1.01 suggests the stock is reasonably priced for its growth.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Revenue Growth, Debt/Equity. Profitability is solid with margins at 28.5% and operating margin at 40.5%. Revenue growth of 36.3% demonstrates continued momentum.
Bear Case : KZIA
The primary concerns for KZIA are EPS Growth, Market Cap, Profit Margin.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Piotroski F-Score.
Key Dynamics to Monitor
KZIA profiles as a hypergrowth stock while REGN is a growth play — different risk/reward profiles.
KZIA carries more volatility with a beta of 2.27 — expect wider price swings.
KZIA is growing revenue faster at 312.4% — sustainability is the question.
REGN generates stronger free cash flow (334M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (78/100 vs 36/100), backed by strong 28.5% margins and 36.3% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kazia Therapeutics Ltd ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Kazia Therapeutics Limited, a biotechnology company focused on oncology, develops anticancer drugs. The company is headquartered in Sydney, Australia.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?